Initial Findings: Methamphetamine Use & Heart Failure Among Native Hawaiians: The Malama Pu'uwai Study

MK Mau, K Asao, J Efird, E Saito, RE Ratner, M Hafi, T Seto

> He Huliau – February 5-7, 2009 Costa Mesa, California





Acknowledgements

J. Keawe'aimoku Kaholokula (Co-I)

Jimmy Efird

Karynna Asao (Summer Intern)

Nobumi Nakamura (Study Coordinator)

Christine Ibanez

Sharlyn Sylva

Gloria Bennett

JoAnn Kimura

L. Ka'ohimanu Dang

Kapiolani Nee

Robert Ratner (MRI)

Muhannad Hafi (MRI)

Todd Seto (Co-PI)

Gerard Akaka (Co-I)

May Vawer (Study Coordinator)

Beth Blackburn

Malia Young

Ruth Aguda-Valenzuela

Ann Cook

Kauka Adjudicators

Dr. Kalani Brady

Dr. Tom Au

Dr. Aaron McMurtray

Methamphetamine Use & Heart Failure in Native Hawaiians & Pacific Island Peoples

- Background
- Methods
- Results
- Conclusions
- Discussion




A Research Partnership: DNHH & QMC



Methamphetamine in the USA

In the West:
persistent
problem - HIGH
areas in:

- Honolulu
- San Diego
- Seattle
- San Francisco
- Los Angeles



What is Methamphetamine?

Methamphetamine vs. Cocaine

Stimulant Stimulant and local anesthetic Man-made Plant-derived Smoking produces a long-lasting high Smoking produces a brief high 50% of the drug is removed from 50% of the drug is removed from the body in 1 hour the body in 12 hours Increases dopamine release and blocks Blocks dopamine re-uptake dopamine re-uptake Limited medical use Limited use as a local anesthetic in some surgical procedures

Methamphetamine, unlike Cocaine, longer duration & larger percentage unchanged in body

Health effects of Methamphetamine






Short-term effects may include:

- Increased attention and decreased fatigue
- Increased activity and wakefulness
- · Decreased appetite
- Euphoria and rush
- Increased respiration
- Rapid/irregular heartbeat
- Hyperthermia


Recovery of Brain Dopamine Transporters in Chronic Methamphetamine (METH) Abusers




Long-term effects may include:

- Addiction
- · Psychosis, including:
 - o paranoia
 - hallucinations
 - repetitive motor activity
- Changes in brain structure and function
- Memory Loss
- Aggressive or violent behavior
- · Mood disturbances
- Severe dental problems
- Weight loss

Illicit Drug Use Trends in Youth (2005-2008)



Methamphetamine Use Trends in Youth (2005-2008)



Methamphetamine Use & Heart Disease

- Less known effects of MU on CV System
- Minorities at high risk Western region
 - NHs, Pacific Island Peoples, etc.
- CVD assoc. with Chronic MU
 - Cardiomyopathy & Heart failure
- Heart failure leading cause of CVD hospitalizations
 - 5.2 million prevalence, \$33.2 billion

Risk factors associated with methamphetamine use and heart failure among Native Hawaiians and other Pacific Island peoples

Marjorie K Mau¹ Karynna Asao² Jimmy Efird³ Erin Saito⁴ Robert Ratner⁵ Muhannad Hafi⁵ Todd Seto⁶

Department of Native Hawaiian Health; ³Biostatistics and Data Management Facility; ⁶Department of Medicine, John A. Burns School of Medicine, University of Hawai'i at Manoa; ²Claremont College; ³Medstar Research Institute

Objective: Heart failure (HF), a long term outcome of chronic methamphetamine use (MU), occurs more frequently in racial and ethnic minority populations at high risk for cardiovascular disparities. This study examined the association of socio-demographic and clinical risk factors with MU among heart failure patients who are Native Hawaiians (NH) or other Pacific Island peoples (PIP).

Design/Setting/Patient Population: Cross-sectional study of NHs and PIPs with advanced heart failure enrolled in the Malama Pu'uwai Study, a randomized control trial to test an educational intervention to reduce re-hospitalization and/or death. A total of 82 participants were enrolled between 6/1 06 to 12/31/07 and met the following eligibility criteria: 1) self-identified NH or PIP 2) Left ventricular systolic ejection fraction ≤45%, 3) Age of 21 years or older. Data were analyzed by odds ratios (OR), 95% confidence intervals (CI), and multiple logistic regression analysis.

Main Outcome Measure: Methamphetamine use.

Results: Twenty-two percent of HF participants were identified as being current or prior methamphetamine users. Younger age and non-married status (combined never married or divorced/separated) were independently associated with MU after adjustment for sex, education, and other co-morbidities associated with HF (ie, age >50 years, OR = 0.16, 95% CI, 0.03–0.84; non-married status combined as never married OR = 8.5, CI, 1.5–47; divorced/separated OR = 11, CI 1.8–75).

Conclusions: Risk factors associated with MU in NH and PIPs with heart failure include: younger age and being divorced/separated or never married. Health care providers should be aware of MU as a contributing factor in the approach and treatment of HF in NHs and PIPs.

Malama Pu'uwai Study (MPS) Methods

- Randomized Control Trial
 - Testing HF education to prevent re-hosp/death
- Eligibility
 - Native Hawaiian or Other Pacific Island People
 - Advanced heart failure (<45% Sys Eject Fraction)
 - age ≥ 21 yr. old
 - recently discharged from hospital
- For this study: Baseline exam
- N = 82 ppts; Jun 2006 Dec 2007

Results – Table 1: Demographic Characteristics

Variable	+ Meth Use	- Meth Use	OR
	N = 18	N = 64	(95% CI)
Age (yrs)	mean = 43 yr	mean = 58 yr	
<40	6 (33%)	6 (9%)	1.0 referent
40-49	6 (33%)	10 (16%)	0.60 (.13-2.7)
> 50	6 (33%)	48 (75%)	0.13 (.0351)
Sex			
Women	4 (22%)	22 (34%)	1.0 referent
Men	14 (78%)	42 (66%)	1.8 (.54-6.2)
Marital Status			
Currently married	2 (11%)	37 (58%)	1.0 referent
Never	10 (56%)	14 (22%)	13 (2.6-68)
Divorced/Separated	5 (28%)	9 (14%)	10 (1.7-62)
Widow/Widower	1 (6%)	4 (6%)	4.6 (.34-63)

Results – Table 1: Demographic Characteristics


Variable	+ Meth Use	- Meth Use	OR
	N = 18	N = 64	(95% CI)
Education			
Less than High Sch	4 (22%)	10 (16%)	1.0 referent
High School/GED	9 (50%)	32 (51%)	.77 (.20-3.0)
Some College	2 (11%)	18 (29%)	.31 (.05-2.0)
College degree	3 (17%)	3 (5%)	2.8 (.39-20)
Race/Ethnicity			
Native Hawaiian	16 (89%)	40 (63%)	1.0 referent
Pacific Island People	2 (11%)	24 (37%)	.21 (.0499)
Smoke (100 cig/life)	16 (89%)	47 (73%)	2.9 (.60-14)
Alcohol (+ 12 mon)	13 (72%)	35 (55%)	2.2 (.68-6.8)

Results – Table 2: Clinical Characteristics

Variable	+ Meth Use	- Meth Use	OR
	N = 18	N = 64	(95% CI)
Systolic BP (mmHg)			
<140	6 (33%)	6 (9%)	1.0 referent
<u>></u> 140	6 (33%)	10 (16%)	1.9 (.32-11)
Diastolic BP (mmHg)			
<90	16 (89%)	59 (92%)	1.0 referent
<u>></u> 90	2 (11%)	5 (8%)	1.5 (.26-8.3)
BMI (kg/m2)			
<30	2 (11%)	22 (34%)	1.0 referent
30-39	8 (44%)	18 (28%)	4.9 (.92-26)
>39	6 (33%)	17 (27%)	3.9 (.70-22)
Unknown	2 (11%)	7 (11%)	3.1 (.37-27)


Results – Table 2: Clinical Characteristics Heart Failure Status*

■ Meth Users (N=18) ■ Non-Meth Users (N=64)



Results: Clinical Characteristics - Co-Morbid Conditions*

■ Meth User (N=18) ■ Non-Meth User (N=64)



Results – Table 3: Multivariate Analysis Factors Associated with Methamphetamine Use; N=82

Factors*	OR (95% CI)	
Age (years)		
Less than 40	1.0 referent	
40 to 50	0.70 (.13-3.9)	
More than 50	0.16 (.0384)	
Marital status		
Currently married	1.0 referent	
Never married	8.5 (1.5-47)	
Divorced/Separated	11 (1.8-75)	
Widow/Widower	5.7 (.38-87)	

^{*} Adjustment for sex, race/ethnicity, education, alcohol use, ASHD, HTN, DM were not significant confounders to model.

Study Conclusion

 Meth use – common among NH/PIPs with heart failure (22%)

Independent risk factors for Meth Use:

- Older age "protective" factor for Meth Use in NH/PIP with heart failure
- Unmarried status associated with Meth Use NH/PIP with heart failure
- Limitations Cross-sectional, sample size


Implications

- Chronic methamphetamine use "hidden" cause of heart failure in 1 of 5 NHs/PIPs
- Native Hawaiian/Pacific Island People w/ HF
 - Younger (~50 y.o. vs. typical 75 y.o.)
 - Etiology more HTN, DM than ASHD (compared Whites)
- HF Survival 40% at 5 years (w/wo EF% preserved)
- Is MU-associated HF reversible compared to other causes of HF?

Approaches for Reducing Heart Failure Disparities in NHOPIs

- Prevent Chronic Methamphetamine Use
 - Improve Social Support systems
 - Increase Programs to Prevent MU Early (i.e. in Youth)
 - Educational programs to raise awareness of CV effects (among other health effects)
- If HF exists treatment approaches need to tx
 - Multiple co-morbidities (DM, HTN, etc.)
 - Recognize that MU may also pose challenges to treatment adherence.

Malama Pu'uwai Study: Open enrollment



Mālama Pu'uwai Study

What's it all about?

The Malama Pu'uwai Study is a randomized control trial (RCT) to test the efficacy of a culturally-informed heart failure (HF) education and support program in Native Hawailans and Pacific Islanders.

The Mālama Pufuwai Study will be conducted by The Queen's Medical Center and the Department of Native Hawaiian Health at JABSOM.

The intervention includes:

- 4 heart education lessons
- 1.Symptoms management
- 2.Medication management
- 3.Low sodium die:
- 4.Physical activity & emotion & stress management
- 1 year follow-up.

Who is eligible?

- Native Hawaiians and Pacific Islanders (for example, Samoans, Tongans, and Marshallese).
- M Adults 21 years of age or older.
- ☑ Clinical symptoms and signs of heart failure AND LV systolic EF of ≤40% OR ≤60% and evidence of abnormal diastolic function on echocardiogram.
- Recently discharged (within 2 weeks) from a hospital admission with heart failure (primary or secondary discharge diagnosis).

All 4 criteria required to enroll

What can you do?

Talk to your doctor to see if you are eligible and if you can benefit from the Malama Puruwai Study.

If your doctor or you need more information, contact us at:

Phone: (808) 587-8577 Email: puuwai@hawaii.edu



I ka 'ai pono ke ola pono

"A healthy life can be achieved by eating right."

Malama Pu'uwai Study

A Research Partnership: DNHH-JABSOM & QMC

